0.829
IF
20
MNiSW
166.26
ICV
Online first
RESEARCH PAPER
 
CC BY-NC-ND 3.0
 
 

Premature atherosclerosis after treatment for acute lymphoblastic leukemia in childhood

Elżbieta Sadurska 1  ,  
 
1
Department of Pediatric Cardiology, Medical University, Lublin, Poland
2
Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Poland
3
Department of Pediatric Radiology, Medical University of Lublin, Poland
4
Department of Pediatric Endocrinology, Medical University of Lublin, Poland
KEYWORDS:
ABSTRACT:
Introduction:
Late cardiovascular complications are the leading causes of morbidity and mortality in patients treated for common malignancies of childhood. Late cardiotoxicity include increased development of atherosclerosis and atherosclerosis – related diseases. An evaluation of the endothelium can be made based on the measurement of endothelium-derived blood vasoactive factors, such as cytokines and adhesion molecules. Their elevated serum levels may serve as sensitive indicators of early atherosclerotic lesions in high risk patients. Currently, assessment of common carotid intima-media thickness has emerged as one of the more powerful tools for evaluation of subclinical atherosclerosis. The purpose of this study was to compare these parameters between patients after antineoplatic treatment compared to persons not exposed to such factors.

Material and Methods:
Early progression of atherosclerotic disease was evaluated in 64 survivors treated for Acute Lymphoblastic Leukaemia (ALL) in childhood, and in a control group of 36 healthy volunteers. Blood serum concentrations of selected new biomarkers, indicative of endothelial damage and inflammatory activity, were measured, including intercellular adhesion molecule-1 (sICAM-1), endothelial leukocyte adhesion molecule-1 (E-selectin), thrombomodulin (TM), interleukin 6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP). The common carotid intima-media thickness (IMT) was also assessed via ultrasound examination.

Results:
Significantly higher blood concentrations of sICAM-1 adhesive molecule (229.3±62.2 ng/mL vs. 199.9 ± 63.3 ng/ mL, p=0.0072) and IL-6 (2.1 ± 2.7 pg/mL vs. 1.9 ± 3.6 pg/mL, p=0.0414) were found in ALL survivors compared with control subjects. Concentration of hs-CRP was also higher in the ALL group: 1.3 ± 2.2 ug/mL vs. 0.6 ± 0.9 ug/mL. This difference was close to statistical significance (p=0.0599). The mean IMT values for right and left carotid arteries were higher in ALL patients after antineoplastic therapy, compared with healthy subjects (IMT-R 0.056±0.008 mm vs. 0.052±0.003 mm; p=0.0021; IMT-L 0.057±0.009 mm vs. 0.052±0.003 mm; p=0.0051).

Conclusions:
Survivors of childhood ALL in the examined group demonstrated elevated concentrations of selected new biomarkers and increased IMT values, compared to controls, which may confirm the occurrence of endothelial injuries in blood vessels. This study indicates that subjects treated for childhood malignancy are at a higher risk of prematurely developing atherosclerosis.

CORRESPONDING AUTHOR:
Elżbieta Sadurska   
Department of Pediatric Cardiology, Medical University, Lublin, Poland
 
REFERENCES (26):
1. Fulbright JM. Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol Res Pract. 2011; 942090. Doi:10.4061/2011/942090.
2. Shankar SM, Marina N, Hudson MM, et al. Cardiovascular Disease Task Force of the Children’s Oncology G. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics. 2008; 121: 387–396.
3. Beń-Skowronek I, Sadurska E, Prazmo-Zaucha A, Brodzisz A, Ruby P, Patel S. Thyroid disorders after oncologic treatment in children. Ann Agric Environ Med. 2014 in press.
4. Oeffinger KC , Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; Oct 12; 355(15): 1572–82.
5. Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol. 2009; 27: 2339–2355.
6. Mulrooney DA, Yeazel M, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer. BMJ 2009; 339: b4606.
7. Chen MH, Collan SD, Diller L, et al. Cardiovascular Disease. Cause of morbidity and mortality in adult survivors of childhood cancers. Circulation Res. 2011; 108: 619–628.
8. Altena R, Perik PJ, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009; 10: 391–99.
9. Balagopal PB, de Ferranti SD, Cook S, et al. Nontraditional Risk Factors and Biomarkers for Cardiovascular Disease: Mechanistic, Research, and Clinical Considerations for Youth: A Scientific Statement From the American Heart Association Circulation 2011; 123: 2749–2769.
10. Urbina EM, Williams RV, Alpert BS, et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: Recommendations for standard assessment for clinical research: A scientific statement from the American Heart Association. Hypertension 2009; 54: 919–950.
11. Poredos P. Intima media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med. 2004; 9: 46–54.
12. Skoczeń S, Armata J, Klus K, et al. Zmodyfikowany program New York w leczeniu dzieci z ALL wykazujących wstępnie liczbę krwinek białych równą lub wyższą niż 50 000/mm3. Protokół Polskiej Grupy Pediatrycznej d/s Leczenia Białaczek i Chłoniaków (PGPLBC). 1997.
13. Campbell M, Castillo L, Dibar E, et al. ALL IC-BFM 2002. A randomized Trial of the I-BFM-SG for the Management of Childhood non-B Acute Lymphoblastic Leukemia. 2002.
14. Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. http://www.nhlbi.nih.gov/guidelines/cvd_ped/index.htm.
15. Adams MJ, Lipshultz SE, Schwartz C, et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol. 2003; 13: 346–356.
16. Chow AY, Chin C, Dahl G, Rosenthal DN. Anthracyclines Cause Endothelial Injury in Pediatric Cancer Patients: A Pilot Study J Clin Oncol. 2006; 24(6): 925 – 928.
17. Sugihara T, Hattori Y, Yamamoto Y, at al. Preferential impairment of nitric oxide-mediated endothelium-dependent relaxation in human cervical arteries after irradiation. Circulation 1999; 100: 635–641.
18. Beckman JA, Thakore A, Kalinowski BH, et al. Radiation therapy impairs endothelium-dependent vasodilation in humans. J Am Coll Cardiol. 2001; 37: 761–76.
19. Murata T, Yamawaki H, Yoshimoto R, et al. Chronic effect of doxorubicin on vascular endothelium assessed by organ culture study. Life Sci. 2001; 69: 2685–2695.
20. Wu S, Ko YS, Teng MS, et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol. 2002; 34: 1596–1607.
21. Grinsky T, Cosset JM. Pulmonary and cardiac late effects of ironizing radiations alone or combined with chemotherapy. Cancer Radiother. 1997; 1: 735–743.
22. Link K, Moell C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab. 2004; 89(10): 5003–5012.
23. Talvensaari KK, Lanning M, Tapanainen P, et al. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab. 1996; 81(8): 3051–3055.
24. Shariat M, Alias NA, Biswal BM. Radiation effects on the intima-media thickness of the common carotid artery in post-radiotherapy patients with head and neck malignancy. Med J. 2008; 84: 609–612.
25. Gianicolo ME, Gianicolo EAL, Tramacere F, et al. Effects of external irradiation of the neck region on intima media thickness of the common carotid artery. Cardiovascular Ultrasound 2010; 8: 8.
26. Meeske KA, Siegel SE, Gilsanz V. Premature carotid artery disease in pediatric cancer survivors treated with neck irradiation. Pediatr Blood Cancer 2009; 53(4): 615–621.
eISSN:1898-2263
ISSN:1232-1966